Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

Nat Med. 2024 Jan;30(1):302. doi: 10.1038/s41591-023-02473-7.

Ingo K Mellinghoff^#¹, Min Lu^#^{2

3}, Patrick Y Wen⁴, Jennie W Taylor⁵, Elizabeth A Maher⁶, Isabel Arrillaga-Romany⁷, Katherine B Peters⁸, Benjamin M Ellingson⁹, Marc K Rosenblum¹⁰, Saewon Chun^{9

11}, Kha Le^{2

12}, Ania Tassinari^{2

13}, Sung Choe^{2

13}, Youssef Toubouti^{2

13

14}, Steven Schoenfeld^{2

13}, Shuchi S Pandya^{2

13}, Islam Hassan^{2

13}, Lori Steelman^{2

13}, Jennifer L Clarke⁵, Timothy F Cloughesy⁹

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA. MellingI@mskcc.org.
² Agios Pharmaceuticals, Cambridge, MA, USA.
³ Mersana Therapeutics, Cambridge, MA, USA.
⁴ Dana-Farber Cancer Institute, Boston, MA, USA.
⁵ University of California San Francisco, San Francisco, CA, USA.
⁶ University of Texas Southwestern Medical Center, Dallas, TX, USA.
⁷ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁸ Duke University Medical Center, Durham, NC, USA.
⁹ University of California, Los Angeles, Los Angeles, CA, USA.
¹⁰ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹¹ California University of Science and Medicine, Colton, CA, USA.
¹² Aligos Therapeutics, South San Francisco, CA, USA.
¹³ Servier Pharmaceuticals LLC, Boston, MA, USA.
¹⁴ Sage Therapeutics, Cambridge, MA, USA.

^# Contributed equally.

No abstract available

Publication types